膀胱影像报告和数据系统(VI-RADS)用于评估膀胱癌全身治疗反应:初步报告
研究前瞻性纳入10例非转移性肌层浸润性膀胱癌(MIBC)患者,在新辅助化疗(NAC)前后行多参数MRI(mpMRI),采用新提出的nacVI-RADS分类评分评估影像学反应(RaR)。结果显示nacVI-RADS分类能与根治性膀胱切除术后病理完全一致地匹配完全病理缓解(pT0)以及部分或微小反应者(仅表现为评分类别下调)。作者认为这是nacVI-RADS可行性的初步证据,可能为癌症特异性生存风险评估及通过主动监测、保膀胱方案或标准治疗指导治疗决策带来范式转变。
要点
- nacVI-RADS基于既往VI-RADS评分、残留病灶、肿瘤大小及固有肌层浸润,分类定义完全影像学反应。
- nacVI-RADS分类与根治性膀胱切除术后病理一致,可匹配完全pT0反应者及部分/微小反应者。
- 初步证据提示nacVI-RADS可能有助于MIBC新辅助化疗后的反应评估。
核心结论
- 本报告为nacVI-RADS标准可行性的初步证据,这些发现可能为癌症特异性生存风险评估以及通过主动监测方案、保膀胱方式或标准治疗指导治疗决策带来可能的范式转变。
研究设计与样本
- 前瞻性研究,连续纳入10例诊断为非转移性肌层浸润性膀胱癌(MIBC)的患者,接受新辅助化疗(NAC),在分期切除术前及化疗周期后行mpMRI,随访MRI评估采用nacVI-RADS算法评估治疗反应。
诊断标准与关键数值
- nacVI-RADS根据既往VI-RADS评分、残留病灶的存在、肿瘤大小及固有肌层浸润,分类定义完全影像学反应(RaR)。
局限性
- 本报告为初步证据,原文结论中提及需要进一步研究以验证nacVI-RADS标准的可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The Vesical Imaging-Reporting and Data System (VI-RADS) criteria are expanding, providing fine differentiation of bladder wall layers involvement. We aimed to explore the feasibility of a novel categorical scoring, the Neoadjuvant chemotherapy VI-RADS (nacVI-RADS) for radiologic assessment of response (RaR), to define the spectrum of treatment response among patients with muscle invasive bladder cancer (MIBC).
METHODS: Ten consecutive patients diagnosed with non-metastatic MIBC were prospectively enrolled and addressed to NAC and underwent mpMRI before staging resection and after the chemotherapy cycles. The follow-up MRI assessment was performed using the nacVI-RADS algorithm for evaluation of response to therapy. NacVI-RADS categorically define complete RaR, based on prior VI-RADS score, presence of residual disease, tumor size, and infiltration of the muscularis propria.
RESULTS: NacVI-RADS categories were able to match all the final radical cystectomy pathology both for complete pT0 responders and for the patients defined as partial or minimal responders, who only showed some RaR inter-scoring class downstaging.
CONCLUSION: This report is the preliminary evidence of the feasibility of nacVI-RADS criteria. These findings might lead to possible paradigmatic shifts for cancer-specific survival risk assessment and to possibly drive the therapeutic decision through active surveillance programs, bladder-sparing modalities, or to the standard of care.
引用
- Pecoraro, Del Giudice, Magliocca, et al. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom Radiol (NY). 2021. PMID: 34919160. doi:10.1007/s00261-021-03365-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。